Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2005 December;164(6) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2005 December;164(6):451-54

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE

A Journal on Internal Medicine and Pharmacology


Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index

 

REVIEWS  


Gazzetta Medica Italiana Archivio per le Scienze Mediche 2005 December;164(6):451-54

Copyright © 2005 EDIZIONI MINERVA MEDICA

language: English

Prosthatic cancer screening is it worth?

Pompa P. 1, Gaspari G. 1, Tucci C. 1, Rossetti R. 1, Martegiani C. 1, Dente D. 1, Paniccia T. 2

1 Urology Division, SS. Annunziata Hospital, Chieti, Italy; 2 Division of Urology, G. D’Annunzio Chieti University, Chieti, Italy


PDF  


Prostatic carcinoma is one of the most frequent male cancer and the second cause of male cancer death. Therefore prostatic cancer screening are performed for a precocious cancer diagnosis and therapy and real decrease in death prostatic cancer. Actually exit two important controlled randomised studies about prostatic cancer screening. The target of the work is to understand if it is possible and effective to introduce prostatic cancer screening in clinical practice and to define costs/benefits. Unfortu-nately the naturale history of the prostatic cancer, the high number of patient to treat after screening studies, the high cost of the practicable therapies don’t justify either the screeneng studies either the following therapies in all patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail